Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 18/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6364700 | 1.00 | CCR8 (0.44) | CCR8THRBRXFP1SLC6A2SLC6A4 | |
| SCHEMBL6254909 | 0.98 | CCR8 (0.44) | CCR8THRBRXFP1SLC6A2SLC6A4 | |
| SCHEMBL6254911 | 0.98 | CCR8 (0.44) | CCR8THRBRXFP1SLC6A2SLC6A4 | |
| SCHEMBL6438547 | 0.89 | CCR8 (0.55) | CCR8 | |
| SCHEMBL6204924 | 0.89 | CCR8 (0.55) | CCR8 | |
| SCHEMBL6364714 | 0.79 | CCR8 (0.54) | CCR8 | |
| SCHEMBL6408725 | 0.79 | CCR8 (0.54) | CCR8 | |
| SCHEMBL6364712 | 0.79 | CCR8 (0.54) | CCR8 | |
| SCHEMBL1338905 | 0.75 | CCR8 (0.54) | CCR8 | |
| SCHEMBL6249952 | 0.75 | CCR8 (0.48) | CCR8SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050085518-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085518-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | CCR8, CCR1, CCR3 | CCR8 1/4885THRB 2120/4885RXFP1 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.